clinical trial · NCT07733947
A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
Caliway Biopharmaceuticals Co., Ltd.·phase3·not yet recruiting·n = 300
Subcutaneous FatCBL-514 Injection0.9 % sodium chloride
brief summary
A Phase 3b, Multicenter, Two stage, Double-blind, Long term Follow up and Open-label Extension Study of Participants Who have Completed the CBL-0301 or CBL-0302 Study for Reducing Abdominal Subcutaneous Fat (Stage 1)
started
Dec 1, 2026
primary completion
Aug 1, 2028
completion
Sep 1, 2028
last updated
Oct 19, 2026
detailed description
A total of approximately 300 adult participants that has received at least one study drug treatment and completed one follow-up visit in the parent studies will be enrolled. Each participant will undergo three follow-up visits, scheduled every three months in Stage 1.
official title
A Phase 3b, Multicenter, Two Stage, Double-blind, Long Term Follow up and Open Label Extension Study of Participants Who Have Completed the CBL-0301 or CBL-0302 Study for Reducing Abdominal Subcutaneous Fat (Stage 1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol